Risk factors of thyroid dysfuction in the anti-virus therapy of chronic hepatitis C
10.13699/j.cnki.1001-6821.2015.16.008
- VernacularTitle:慢性丙型病毒性肝炎治疗中发生甲状腺功能异常的危险因素
- Author:
Min-Zhen YE
1
;
Qing XIE
;
Cui-Ling CHEN
Author Information
1. 上海交通大学医学院 附属瑞金医院 感染科
- Keywords:
chronic hepatitis C;
anti-virus therapy;
thyroid dysfunction;
risk factor
- From:
The Chinese Journal of Clinical Pharmacology
2015;(16):1585-1587
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore risk factors of thyroid dysfunction during anti -virus therapy in patients with chronic hepatitis C. Methods A total of 131 patients with chronic hepatitis C who received IFN-α-2a 180 μg once a week and ribavirin 15 mg? kg -1 , qd were chosen.The treatment lasted 48 weeks.The data of thyroid function and thyroid antibodies [FT3, FT4, TSH, antithyroid peroxidase autoantibody (TPOAb), and thyroglobulin antibody (TGAb)] were tested within 2 weeks before therapy and 12, 24, 36 and 48 weeks during the course. Results In 131 cases of chronic hepatitis C, the incidence of thyroid dysfunction was 10.69%(14/131).The incidence of TGAb at baseline positive in thyroid dysfunction group was significantly higher than that in normal thyroid function group ( 35.7% vs 7.7%, P<0.05) . The incidence of TPOAb at baseline positive in thyroid dysfunction group was significantly higher than that in normal thyroid function group (57.1%vs 0.9%, P<0.05 ) .There was no significant differences in the data of sex, age, and period of treatment of interferon in the area of thyroid dysfunction.Conclusion Presence of elevated TGAb and TPOAb are the main risk factors for the thyroid dysfunction during anti -virus therapy in patients with chronic hepatitis C.TGAb and TPOAb can be used as untoward effect monitoring indexes during the anti-virus therapy.
